Sam Meiklejohn

Cooley advised Silence Therapeutics in a $56.5 million registered direct offering of 5,950,000 American Depositary Shares (ADS), each representing three ordinary shares, at a price of $9.50 per ADS. Silence is a biotechnology company focused on discovering and developing molecules incorporating novel short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Partners Josh Kaufman, Div Gupta, Nicolas H.R. Dumont and Claire Keast-Butler led the Cooley team.

Cooley is advising Grindr, the #1 social network for the LGBTQ+ community, on its definitive agreement to merge with special purpose acquisition company (SPAC) Tiga Acquisition Corp. – a combination that will result in Grindr becoming a publicly listed company. Partners Dave Peinsipp, Jamie Leigh, Kristin VanderPas, Garth Osterman, Will Cai, Jeffrey Tolin and Aaron Pomeroy, as well as associates Sangitha Palaniappa, Kyle Huh, JJ Meng, Dannielle Antone, Mike Lam and Meera Patel, led the Cooley team advising Grindr.

Cooley advised Thayer Ventures Acquisition Corp., a publicly traded special purpose acquisition company affiliated with Thayer Ventures, on its completed business combination with innovative luxury travel subscription brand Inspirato. Lawyers Daniel Peale, John McKenna, Milson Yu, Michelle Peleg, Shawn Fateh, Jonathan Camello, Brian Kloeblen and Angel Nwachukwu led the Cooley team advising Thayer Ventures.

Cooley advised the underwriters on Centessa Pharmaceuticals’ $380 million initial public offering of 18,975,000 American depositary shares ADSs, which includes the full exercise of the underwriters’ option to purchase additional shares. Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Evercore Group LLC, acted as joint book-running managers for the offering. Centessa Pharmaceuticals, whose securities now trade on the Nasdaq Global Select Market under the symbol “CNTA,” is a clinical-stage company employing its asset-centric business model to discover, develop and deliver impactful medicines to patients. Partners Div Gupta, Claire Keast-Butler, Josh Kaufman and Geoffrey Starr led the Cooley team.

Cooley advised Immunocore on its $297.1 million initial public offering of 11,426,280 American depositary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Immunocore, whose securities now trade on the Nasdaq Global Market under the symbol IMCR, is a late-stage biotechnology company pioneering the development of a novel class of T-cell receptor bispecific immunotherapies designed to treat a broad range of diseases. Partners Div Gupta, Eric Blanchard, Nicola Maguire and Claire Keast-Butler led the Cooley team.